IPercept invests in RunwayFBU
Funding Provisional 86% confidence first seen
Tech.eu reports that in IPercept’s $16.5M Series A funding round, RunwayFBU participated as an existing investor. The round was co-led by Isogon Ventures and 2150, with participation from Luminar Ventures, J12 Venture, and AI.Fund. This matters because RunwayFBU’s involvement ties it to IPercept’s push to expand predictive maintenance offerings—also planned for a US launch—using its AI technology for CNC machine wear and degradation.
The deal
IPercept $16.5M Series A · announced 29 Sep 2026
Investors Isogon Ventures 2150 Luminar Ventures RunwayFBU J12 Venture AI.Fund
Deal terms as reported in the coverage below.
Decision brief
- What changed
- IPercept closed a $16.5 million Series A round co-led by Isogon Ventures and 2150, with participation from RunwayFBU, Luminar Ventures, J12 Venture, and AI.Fund. The company said it will use the funding to improve its AI-based predictive maintenance technology for CNC machines and to launch in the US with initial local hires.
- Why it matters
- For business leaders evaluating industrial AI partnerships or competitive positioning, this financing gives IPercept more resources to expand product development and geographic reach at the same time. RunwayFBU’s participation links it to a company that is moving from current deployments toward broader commercialization, which could matter for firms tracking investor-backed momentum in industrial predictive maintenance. Decision-makers should care because the combination of fresh capital, named enterprise users, and planned US expansion can affect partner choices, competitive monitoring, and market entry timing in factory AI.
- Evidence
- The information comes from a single Tech.eu report stating that IPercept raised $16.5 million, naming the co-leads and participating investors including RunwayFBU, and outlining planned uses of funds such as US hiring and AI improvement. The same report also says the technology is already used by Airbus, Bosch, and Volvo, but no second independent source is provided in the coverage supplied here.
- What remains uncertain
- The coverage does not specify the size of RunwayFBU’s participation, its governance rights, or whether this investment changes IPercept’s strategic direction beyond providing capital. It also does not verify timelines, customer expansion, or the commercial impact of the planned US launch, so any assumptions about market share gains or investor influence remain unconfirmed.
- Monitor next
- Watch for IPercept’s first announced US hires, customer wins, or commercial launch details that show whether the Series A is translating into actual North American expansion.
Analytical support, not advice — assumptions and open questions stated above.